Fate Therapeutics Inc
(NAS:FATE)
$
3.21
0.04 (1.26%)
Market Cap: 365.40 Mil
Enterprise Value: 79.38 Mil
PE Ratio: 0
PB Ratio: 0.86
GF Score: 57/100 - Q4 2023 Fate Therapeutics Inc Earnings Call TranscriptFeb 26, 2024$6.95 (-0.14%)Earnings
- Q3 2023 Fate Therapeutics Inc Earnings Call TranscriptNov 08, 2023$2.33 (+0.87%)Earnings
- Q2 2023 Fate Therapeutics Inc Earnings Call TranscriptAug 08, 2023$3.53 (-0.56%)Earnings
- Fate Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 13, 2023
- Fate Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Fate Therapeutics Inc Earnings Call TranscriptMay 03, 2023$6.32 (+6.76%)Earnings
- Fate Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2023
- Q4 2022 Fate Therapeutics Inc Earnings Call TranscriptFeb 28, 2023$6.12 (+1.83%)Earnings
- Fate Therapeutics Inc at Cowen IO Next Summit (Virtual) TranscriptNov 11, 2022
- Q3 2022 Fate Therapeutics Inc Earnings Call TranscriptNov 03, 2022$19.45 (-2.94%)Earnings
- Fate Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2022
- Q2 2022 Fate Therapeutics Inc Earnings Call TranscriptAug 03, 2022$32.81 (+7.12%)Earnings
- Fate Therapeutics Inc at Bank of America Healthcare Conference TranscriptMay 12, 2022
- Q1 2022 Fate Therapeutics Inc Earnings Call TranscriptMay 04, 2022$30.69 (+6.64%)Earnings
- Fate Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 16, 2022
- Q4 2021 Fate Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$34.55 (-1.09%)Earnings
- Fate Therapeutics Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) TranscriptFeb 09, 2022
- Fate Therapeutics Inc Phase 1 FT516 and FT596 Clinical Data Update Call TranscriptDec 14, 2021
- Fate Therapeutics Inc Investor Event - Corporate Call TranscriptNov 15, 2021
- Q3 2021 Fate Therapeutics Inc Earnings Call TranscriptNov 04, 2021$59.65 (-1.21%)Earnings
- Fate Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 10, 2021
- Fate Therapeutics Inc Interim Phase 1 Clinical Data for NHL Programs Call TranscriptAug 19, 2021
- Q2 2021 Fate Therapeutics Inc Earnings Call TranscriptAug 04, 2021$85.73 (+2.98%)Earnings
- Fate Therapeutics Inc at Bank of America NAPA Healthcare Conference TranscriptJun 15, 2021
- Fate Therapeutics Inc Annual Shareholders Meeting TranscriptJun 02, 2021
- Fate Therapeutics Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 01, 2021
- Fate Therapeutics Inc Interim Phase 1 Clinical Data for AML Programs Corporate Call TranscriptMay 13, 2021
- Q1 2021 Fate Therapeutics Inc Earnings Call TranscriptMay 05, 2021$77.73 (-2.51%)Earnings
- Fate Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 11, 2021
- Fate Therapeutics Inc at SVB Leerink Global Healthcare Conference (Virtual) TranscriptFeb 25, 2021
- Q4 2020 Fate Therapeutics Inc Earnings Call TranscriptFeb 24, 2021$95.27 (-0.22%)Earnings
- Q3 2020 Fate Therapeutics Inc Earnings Call TranscriptNov 05, 2020$49.92 (+0.20%)Earnings
- Q2 2020 Fate Therapeutics Inc Earnings Call TranscriptAug 05, 2020$32.84 (+0.67%)Earnings
- Q1 2020 Fate Therapeutics Inc Earnings Call TranscriptMay 11, 2020$30.22 (+4.79%)Earnings
- Q4 2019 Fate Therapeutics Inc Earnings Call TranscriptMar 02, 2020$31.01 (+6.20%)Earnings
- Q3 2019 Fate Therapeutics Inc Earnings Call TranscriptNov 05, 2019$15.71 (+2.68%)Earnings
- Fate Therapeutics, Inc. Presents at Citi's 14th Annual Biotech Conference, Sep-04-2019 01:30 PM TranscriptSep 04, 2019
- Q2 2019 Fate Therapeutics Inc Earnings Call TranscriptAug 06, 2019$19.82 (+2.85%)Earnings
- Q1 2019 Fate Therapeutics Inc Earnings Call TranscriptMay 07, 2019$16.98 (-5.19%)Earnings
- Q4 2018 Fate Therapeutics Inc Earnings Call TranscriptMar 05, 2019$16.03 (-1.05%)Earnings
Fate Therapeutics, Inc. Presents at Citi's 14th Annual Biotech Conference, Sep-04-2019 01:30 PM Transcript
Sep 04, 2019 / 05:30PM GMT
Release Date Price:
$16.81
(-0.83%)
Yigal Dov Nochomovitz
Citigroup Inc, Research Division - Director
The next panel is cell therapy, up-and-comers in the cell therapy space. So it's my pleasure to introduce our 3 distinguished guests, from Atara the CEO, Pascal Touchon; and from Cellectis, André Choulika; and, of course, from Fate, in the middle, Scott Wolchko. So welcome all of you. Thanks for making the time.
Questions & Answers
Yigal Dov Nochomovitz
Citigroup Inc, Research Division - Director
I guess the question I have to start out the session is at a 30,000-foot level, could each of you give your thoughts on what are the ingredients to create a successful cell therapy? What are the things you want to do? And what are the things that you absolutely want to avoid on the path to a product that's a cell-based therapy? So you want to kick it off, Pascal?
Pascal Touchon;Yigal Dov Nochomovitz<
Atara Biotherapeutics, Inc. - President, CEO & Director
Yes, with pleasure. I mean thank you for inviting me, by the way.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)